Oral GnRH antagonist Relugolix achieves faster, deeper testosterone suppression and 54% reduced cardiovascular risk in advanced prostate cancer.
[Relugolix : the first oral GnRH receptor antagonist for the treatment of advanced hormone-sensitive prostate cancer].
Abstract
Relugolix, an oral GnRH antagonist, demonstrated superior testosterone suppression and a 54% reduction in major adverse cardiovascular events compared to leuprolide in advanced prostate cancer.